Judy Truong

Judy Truong

Auto-generated profile, based on publicly available information

Judy Truong

University of Toronto

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
JTJudy Truong
Judy Truong
AYAndrew T. Yan
Andrew T. Yan
GCGemma Cramarossa
Gemma Cramarossa
KCKelvin Chan
Kelvin Chan

1 April 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
JTJ. Truong
J. Truong
ELE. K. Lee
E. K. Lee
MTM. E. Trudeau
M. E. Trudeau
KCKelvin Chan
Kelvin Chan
Background Guidelines recommend primary prophylaxis (PP) with granulocyte colony stimulating factors (G-CSF) for patients above a febrile neutropenia (FN) risk threshold of 20%. Practitioners often use FN rates of regimens based on data from randomized controlled trials (RCTs), which are often comprised of highly selected patients. Patients in the community setting may be at higher risk of FN. Materials and Methods A systematic literature search was conducted for full-length articles reporting FN rates for breast cancer-related chemotherapies between January 1996 and February 2014. A regimen was included if there was at least one RCT and one observational study. Meta-regression was used to model the odds of FN. Results 130 studies involving 29 regimens and 50,069 patients were identified. 65 observational study (n=7,812) and 110 RCT (n=42,257) cohorts were included. The unadjusted FN rate was 11.7% in observational and 7.9% in RCT cohorts. The univariable odds ratio (OR) for FN in the observational study compared to RCT cohorts was 1.58 (95% CI: 1.09-2.28; p=0.017). The FN rates remained significantly higher in the observational study compared to RCT cohorts (OR=1.74; 95% CI: 1.15-2.62; p=0.012) after adjusting for age, chemotherapy intent and regimen; this meant that a 13% (95% CI: 8.7%-17.9%) FN rate in RCT would translate into 20% FN rate in observational study. Conclusions FN rates in the observational studies are significantly higher than suggested by RCTs. Guidelines should clarify how FN rates from RCTs should be applied in clinical practice. Large population-based studies are needed to confirm FN rates in the real world.

22 June 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
JTJudy Truong
Judy Truong
MCMatthew C. Cheung
Matthew C. Cheung
HMHelen Mai
Helen Mai
Jessa LetargoJessa Letargo
Jessa Letargo
ACAlexandra Chambers
Alexandra Chambers
KCKelvin Chan
Kelvin Chan

27 May 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JTJudy Truong
Judy Truong
KCKelvin Chan
Kelvin Chan
HMHelen Mai
Helen Mai
ACAlexandra Chambers
Alexandra Chambers
MSMona Sabharwal
Mona Sabharwal
MCMatthew C. Cheung
Matthew C. Cheung
Background: The soaring costs of anti‐cancer drugs pose a threat to the sustainability of cancer care. The pricing strategy chosen by manufacturers can impact the costs of oral anti‐cancer drugs during dose modifications, but this issue remains under‐recognized in the literature. In general, with the flat pricing strategy, there is a single fixed price for each tablet regardless of dosage strength, whereas with linear pricing, the price of each tablet increases with its dose. We hypothesize that flat pricing will have increased drug costs compared to linear pricing during dose reductions since the cost remains fixed despite decreased dose requirements. This practice may have significant financial implications considering the high costs, extensive utilization, and frequent occurence of dose reductions with anti‐cancer drugs. Methods: Oral anti‐cancer drugs reviewed by the pan‐Canadian Oncology Drug Review program between 2011 and 2018 were identified. The cost per mg and cost per 28‐day cycle were calculated for dose levels −2 to +2. The percent change in cost per mg and cost per cycle during dose modifications from the standard dose were calculated. We conducted Mann‐Whitney U and Fisher‐exact tests to compare the association between drug costs during dose reductions and pricing strategy.Results: In this study, 30 oral anti‐cancer drugs for use in 41 indications were analyzed; 44% of drugs used linear pricing and 56% used flat pricing. Dose reductions increased the mean cost per mg for drugs with linear pricing by 14.7% (range: 0%‐50%) at dose level −1 and 17.2% (range: 0%‐50%) at dose level −2 and flat pricing by 60.8% (range: 19%‐100%) at dose level −1 and 99.1% (range: 0%‐300%) at dose level −2. The cost per mg was significantly increased in drugs using flat pricing compared to linear pricing when dose reduction to either level ‐1 (P = 0.010) or level ‐2 (P = 0.006) occurred. The mean cost per cycle was decreased for drugs using linear pricing by 20.9% (range: −40% to 0%) at dose level −1 and 48.7% (range: −60% to −25%) at dose level −2 and flat pricing by 0.8% (range −6% to 0%) at dose level −1 and 11.0% (range: −50% to 100%) at dose level −2. The cost per cycle was significantly decreased in drugs with linear pricing compared to flat pricing when the standard dose is reduced to either dose level ‐1 (P = 0.005) or dose level ‐2 (P = 0.026).Conclusions: Overall, flat pricing had significantly greater costs compared to linear pricing during dose reductions of anti‐cancer drugs. While there is a general expectation that the cost of drugs should decrease with dose reduction, drugs with flat pricing were generally found to have increased cost per mg and no change in the cost per cycle. The resultant increased spending on drug acquisition (despite purchasing lower doses) lead to financial wastage, which has significant implications on cost‐effectiveness considerations and budgets. Future economic evaluations should take into consideration the hidden costs associated with dose reductions of flat priced drugs.

24 January 2023 in Canadian Medical Education Journal
Verified
Journal Article
Open access
PDF file
JTJudy Truong
Judy Truong
PSPriya Sandhu
Priya Sandhu
VSVanessa Sheng
Vanessa Sheng
YSYasamin Sadeghi
Yasamin Sadeghi
FLFokhan Leung
Fokhan Leung
SSShazeen Suleman
Shazeen Suleman
Background: Health advocacy is a core competency for physicians, which can be developed through community-based service-learning (CBSL). This exploratory study investigated the experiences of community partner organizations (CPOs) participating in CBSL in the context of health advocacy. Methods: A qualitative study was conducted. Nine CPOs at a medical school participated in interviews on topics pertaining to CBSL and health advocacy. Interviews were recorded, transcribed, and coded. Major themes were identified. Results: CPOs perceived a positive impact from CBSL through student activities and connecting with the medical community. There was no unifying definition of health advocacy. Advocacy activities varied depending on the individual’s role (i.e., CPO, physician, and student), which encompassed providing patient care or services, raising awareness of healthcare issues, and influencing policy changes. CPOs had different perceptions of their role in CBSL from facilitating service-learning opportunities to teaching students in CBSL, while a few desired to be involved in curriculum development. Conclusion: This study provides further insight into health advocacy from the lens of CPOs, which may inform changes to health advocacy training and the CanMEDS Health Advocate Role to better align with the values of community organizations. Engaging CPOs in the broader medical education system may improve health advocacy training and ensure a positive bidirectional impact.
1